title: [A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women].
abstract: To assess efficacy and toxicity of less toxic analogs for advanced breast cancer in elderly women, we performed a phase II study using the combination mitoxantrone (MTZ)-vinorelbine (VNR). From January 1991 to May 1993, 25 women older than 70 years received a chemotherapy consisting in 10 mg/m2 of MTZ on day 1, followed by 20 mg/m2 of VNR on day 1 and 8. Cycles were repeated every 21 days for a maximum of ten cycles in the case of an objective response. Sixteen women previously received first line hormonotherapy, eight with only one metastatic site. Twenty-three patients are evaluable for response and toxicity. An objective response was observed in five cases (22%), with a median time to progression of 13 months. More than 75% of the planned dose-intensity, for MTZ and VNR was received by 90 and 57.2% of patients, respectively. Dose-limiting toxicity was myelosuppression but no febrile neutropenia was observed. Extra haematologic toxicities were unfrequent. This combination is well tolerated by elderly women, but best results could be achieved by increasing delivered dose intensity.
authors.affiliation: Département d'oncologie médicale, centre Claudius-Regaud, Toulouse, France.
authors.forename: L
authors.initials: L
authors.lastname: Gladieff
authors.forename: P
authors.initials: P
authors.lastname: Houyau
authors.forename: J
authors.initials: J
authors.lastname: Mihura
authors.forename: M
authors.initials: M
authors.lastname: Martinez
authors.forename: N
authors.initials: N
authors.lastname: Caunes
authors.forename: C
authors.initials: C
authors.lastname: Chevreau
authors.forename: R
authors.initials: R
authors.lastname: Bugat
authors.forename: H
authors.initials: H
authors.lastname: Roché
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000009:adverse effects; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000139:chemically induced; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D008942:Mitoxantrone; D000077235:Vinorelbine
vernacular_title: Etude de phase II d'association mitoxantrone-vinorelbine dans le traitement du cancer du sein de la femme âgée.